市场调查报告书
商品编码
1320992
内分泌检测市场 - 按测试类型(人绒毛膜促性腺激素 (hCG) 激素测试、胰岛素测试)、按技术(质谱、免疫分析)、按最终用途(医院、临床实验室)和预测,2023 - 2032 年Endocrine Testing Market - By Test Type (Human Chorionic Gonadotropin (hCG) Hormone Test, Insulin Test), By Technology (Mass Spectroscopy, Immunoassay), By End-use (Hospitals, Clinical Laboratories) & Forecast, 2023 - 2032 |
全球内分泌检测市场将在 2023 年至 2032 年间出现显着增长。
全球老年人口的持续增长将推动未来十年的行业增长。据世界卫生组织称,到2050年,60岁以上的人口将占世界人口的22%。老年人更容易患内分泌疾病,如糖尿病、甲状腺功能障碍和肾上腺疾病,需要准确的诊断测试,从而为市场拓展做出贡献。诊断技术的技术进步和创新内分泌检测产品的推出也在推动市场增长方面发挥着至关重要的作用。此外,个人对预防保健和早期疾病检测的认识不断增强,推动了内分泌检测的采用,从而推动了市场收入。
整体内分泌检测市场份额根据测试、技术、最终用途和地区进行分类。
就测试而言,到 2032 年,胰岛素细分市场有望占据相当大的市场份额。对胰岛素测试的需求主要是由全球糖尿病患病率不断上升推动的。根据 CDC 2022 年国家糖尿病统计报告,估计美国有 1.3 亿成年人患有糖尿病或糖尿病前期。随着糖尿病病例持续增加,准确测量胰岛素水平对于有效的疾病管理和个性化治疗计划至关重要。胰岛素测试在诊断糖尿病、监测治疗效果和预防并发症方面发挥着关键作用,导致对此类测试的持续需求。
在技术方面,到2032年,色谱领域的内分泌检测行业规模将以显着的复合年增长率扩大。色谱检测高度灵敏和准确,可以同时分析多种激素。该技术可有效分离和检测复杂的激素混合物,有助于精确诊断和监测内分泌失调。对可靠和全面的诊断方法不断增长的需求正在推动内分泌学领域采用基于色谱的测试。
预计到 2032 年,诊断中心将成为内分泌检测的主要最终用户。内分泌疾病的患病率不断增加,加上人口老龄化,迫切需要准确、及时的激素评估。此外,检测技术的进步使内分泌检测变得更加容易,从而在诊断中心得到更高的采用,从而能够及早发现和有效管理内分泌相关疾病。
到 2032 年,欧洲内分泌检测行业将录得可观收入。该地区人口老龄化导致内分泌疾病患病率更高,从而增加了对综合检测的需求。此外,人们对预防保健和早期疾病检测的认识不断提高,推动了对内分泌检查的需求,有助于及时干预和治疗。诊断技术的进步也使内分泌检测变得更加容易,进一步推动了其在欧洲的普及。
Global Endocrine Testing Market will register significant growth between 2023 and 2032.
The consistent rise in the geriatric population worldwide will drive industry growth over the next ten years. According to WHO, people aged over 60 years will account for 22% of the world's population by 2050. Aging people have a greater susceptibility to endocrine disorders, such as diabetes, thyroid dysfunction, and adrenal gland disorders, that require accurate diagnostic tests, thereby contributing to market expansion. Technological advancements in diagnostic techniques and the introduction of innovative endocrine testing products are also playing a crucial role in fueling market growth. Moreover, the growing awareness among individuals regarding preventive healthcare and early disease detection is propelling the adoption of endocrine testing, driving market revenues.
The overall endocrine testing market share is categorized based on test, technology, end-use, and region.
Regarding the test, the insulin segment is poised to capture a decent market share by 2032. The demand for insulin tests is primarily driven by the escalating prevalence of diabetes worldwide. According to CDC 2022 National Diabetes Statistics Report, an estimated 130 million adults in the US are living with diabetes or prediabetes. As diabetes cases continue to rise, the need to accurately measure insulin levels becomes essential for effective disease management and personalized treatment plans. Insulin tests play a critical role in diagnosing diabetes, monitoring treatment efficacy, and preventing complications, contributing to the sustained demand for such tests.
In terms of technology, the endocrine testing industry size from the chromatography segment will expand at a notable CAGR through 2032. Chromatography testing is highly sensitive and accurate and can analyze multiple hormones simultaneously. This technique offers efficient separation and detection of complex hormone mixtures, aiding in precise diagnosis and monitoring of endocrine disorders. The growing demand for reliable and comprehensive diagnostic methods is propelling the adoption of chromatography-based testing in the field of endocrinology.
Diagnostic centers are anticipated to emerge as a prominent end-user for endocrine testing by 2032. The increasing prevalence of endocrine disorders, coupled with the aging population, drives the need for accurate and timely hormone assessments. Moreover, advancements in testing technologies have made endocrine assays more accessible, leading to higher adoption in diagnostic centers, enabling early detection and effective management of endocrine-related conditions.
Europe endocrine testing industry will record significant revenue through 2032. The region's aging population contributes to a higher prevalence of endocrine disorders, increasing the need for comprehensive testing. Additionally, rising awareness about preventive healthcare and early disease detection fuels the demand for endocrine tests, aiding in timely intervention and treatment. Advances in diagnostic technologies also make endocrine testing more accessible, further driving its popularity in Europe.